{
    "clinical_study": {
        "@rank": "4839", 
        "acronym": "HALPCARD", 
        "arm_group": [
            {
                "arm_group_label": "Haloperidol", 
                "arm_group_type": "Active Comparator", 
                "description": "Haloperidol 1mg the night before and 1mg the morning of surgery"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 dose the night before and 1 dose the morning of surgery"
            }
        ], 
        "brief_summary": {
            "textblock": "Will the use of prophylactic Haloperidol for patients undergoing open heart surgery reduce\n      the incidence, duration, and severity of post cardiotomy delirium?"
        }, 
        "brief_title": "Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Postoperative Confusion", 
        "condition_browse": {
            "mesh_term": [
                "Confusion", 
                "Delirium"
            ]
        }, 
        "detailed_description": {
            "textblock": "Pilot study for feasibility and safety, n = 40, haloperidol 1mg vs. placebo BID\n      admisnistered night before and day of surgery, then continued for total 72hrs post-op, if\n      delirium occurs study drug is stopped and ususal standard of care implemented by MRP."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Greater than or equal to 70 years of age, undergoing open heart surgery, with one of\n             the following risk factors for post-op delirium:\n\n               -  TIA/Stroke;\n\n               -  Euroscore greater than or equal to 5;\n\n               -  abnormal clock draw.\n\n        Exclusion Criteria:\n\n          -  Parkisonism,\n\n          -  on any antipsychotic medications pre-op,\n\n          -  active delirium,\n\n          -  emergent surgery,\n\n          -  Haloperidol allergy,\n\n          -  schizophrenia,\n\n          -  prolonged QTc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "70 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862302", 
            "org_study_id": "HALPCARD-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Haloperidol", 
                "description": "1mg the night before and 1mg the morning of surgery", 
                "intervention_name": "Haloperidol", 
                "intervention_type": "Drug", 
                "other_name": "Haldol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "1 dose the night before and 1 dose the morning of surgery", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Haloperidol", 
                "Haloperidol decanoate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prevention delirium", 
            "Cardiac surgery"
        ], 
        "lastchanged_date": "July 25, 2013", 
        "location": {
            "contact": {
                "email": "lamyand@hhsc.ca", 
                "last_name": "Andre Lamy, MD", 
                "phone": "905-527-4322", 
                "phone_ext": "40325"
            }, 
            "facility": {
                "address": {
                    "city": "Hamilton", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "L8L 2X2"
                }, 
                "name": "Hamilton Health Sciences"
            }, 
            "investigator": {
                "last_name": "Andre Lamy, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium: A Randomized Placebo-Controlled Pilot Study", 
        "other_outcome": {
            "measure": "An economic analysis will be completed to determine if Haloperidol prophylaxis resulted in any cost savings", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed for the duration of their hospital stay to a maximum of 30 days"
        }, 
        "overall_contact": {
            "email": "lamyand@hhsc.ca", 
            "last_name": "Andre Lamy, MD", 
            "phone": "905-527-4322", 
            "phone_ext": "40325"
        }, 
        "overall_official": {
            "affiliation": "McMaster University", 
            "last_name": "Andre Lamy, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "If a participant does not develop delirium post operatively, then the confusion assessment method (CAM)will be monitored for 24 hours after the study medication ends. Patients will be followed up until seven days or until discharge if no delirium occurs, or if delirium is detected, up to 30 days or until discharge", 
                "measure": "Feasibility of conducting a trial utilizing low dose Haloperidol use in patients post cardiac surgery", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of their hospital stay to a maximum of 30 days."
            }, 
            {
                "description": "If a participant does not develop delirium post operatively, then the confusion assessment method (CAM)will be monitored for 24 hours after the study medication ends. Patients will be followed up until seven days or until discharge if no delirium occurs, or if delirium is detected, up to 30 days or until discharge", 
                "measure": "Safety monitoring of low dose Haloperidol use in patients post cardiac surgery", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of their hospital stay to a maximum of 30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862302"
        }, 
        "responsible_party": {
            "investigator_affiliation": "McMaster University", 
            "investigator_full_name": "Andre Lamy", 
            "investigator_title": "Dr Andre Lamy, MD, FRCSC, MHSc, Cardiac Surgeon", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "The incidence of delirium", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of their hospital stay to a maximum of 30 days"
            }, 
            {
                "measure": "Delirium severity", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of their hospital stay to a maximum of 30 days"
            }, 
            {
                "measure": "Total length of stay (LOS), with breakdown for intensive care unit (ICU) days and ward days", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of their hospital stay to a maximum of 30 days"
            }, 
            {
                "measure": "Duration of delirium", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of their hospital stay to a maximum of 30 days"
            }
        ], 
        "source": "McMaster University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "McMaster University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}